Article
Impact of body surface area on efficacy and safety in patients with EGFR-mutant non-small cell lung cancer treated with osimertinib as a first-line treatment.
Cancer treatment and research communications - 1 Jan 2024
Tanaka Saki, Tamiya Motohiro, Nishiuma Satoshi, Nakamura Sayaka, Nozaki Keisuke, Watanabe Naoko, Itoh Chisae, Kadokawa Yukio, Takeda Kenji, Takahashi Kozo, Miyazaki Akito, Kawamura Takahisa, Kunimasa Kei, Inoue Takako, Nishino Kazumi, Takagi Mari
Abstract excerpt
BACKGROUND: The most recommended treatment for stage IV EGFR-positive lung cancer is osimertinib monotherapy. The dosage of osimertinib is fixed at 80 mg/day regardless of body surface area (BSA), however some patients withdraw or reduce the dosage due to adverse events (AEs). METHODS: We performed a retrospective cohort study of 98 patients with EGFR mutation-positive non-small cell lung cancer (NSCLC), who...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.